AbbVie Inc (ABBV)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $521.50B
Last updated: Nov 17, 2026 at 11:05 AM ET
AbbVie Inc (ABBV) Earnings: Report Dates and Results
AbbVie (ABBV) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, AbbVie reported EPS of $3.82, above the $3.74 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ABBV has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 45.8% above the $2.71 reported for the quarter ended Dec 31, 2025.
ABBV Earnings Call
The latest ABBV earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, ABBV beat 35, missed 4 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $17.40B, up 10.3% from $15.78B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $3.82 | $3.74 | $3.61 - $3.86 | +2.14% | Beat | +105.4% | 22 | 0 up, 8 down | Oct 30, 2026 | $17.40B |
| Jun 30, 2026 | $3.65 | $3.64 | $3.54 - $3.71 | +0.27% | Beat | +22.9% | 22 | 1 up, 1 down | Jul 31, 2026 | $16.99B |
| Mar 31, 2026 | $2.65 | $2.67 | $2.57 - $3.01 | -0.75% | Miss | +7.7% | 23 | 0 up, 15 down | Apr 29, 2026 | $15.00B |
| Dec 31, 2025 | $2.71 | $2.65 | $2.62 - $2.77 | +2.26% | Beat | +25.5% | 17 | 0 up, 13 down | Feb 4, 2026 | $16.62B |
| Sep 30, 2025 | $1.86 | $1.78 | $1.67 - $1.98 | +4.49% | Beat | -38.0% | 18 | 0 up, 14 down | Oct 31, 2025 | $15.78B |
| Jun 30, 2025 | $2.97 | $2.91 | $2.82 - $3.19 | +2.06% | Beat | +12.1% | 20 | 0 up, 14 down | Jul 31, 2025 | $15.42B |
| Mar 31, 2025 | $2.46 | $2.40 | $2.34 - $2.53 | +2.50% | Beat | +6.5% | 18 | 1 up, 4 down | Apr 25, 2025 | $13.34B |
| Dec 31, 2024 | $2.16 | $2.12 | $2.06 - $2.98 | +1.89% | Beat | -22.6% | 18 | 0 up, 6 down | Jan 31, 2025 | $15.10B |
| Sep 30, 2024 | $3.00 | $2.92 | $2.88 - $2.96 | +2.74% | Beat | +1.7% | 18 | 0 up, 1 down | Oct 30, 2024 | $14.46B |
| Jun 30, 2024 | $2.65 | $2.66 | N/A | -0.38% | Miss | -8.9% | 18 | 0 up, 3 down | Jul 25, 2024 | $14.46B |
| Mar 31, 2024 | $2.31 | $2.23 | $2.18 - $2.30 | +3.59% | Beat | -6.1% | 13 | 1 up, 3 down | Apr 26, 2024 | $12.31B |
| Dec 31, 2023 | $2.79 | $2.77 | $2.71 - $2.94 | +0.72% | Beat | -22.5% | 17 | 1 up, 6 down | Feb 2, 2024 | $14.30B |
| Sep 30, 2023 | $2.95 | $2.87 | N/A | +2.79% | Beat | -19.4% | 17 | 3 up, 1 down | Oct 27, 2023 | $13.93B |
| Jun 30, 2023 | $2.91 | $2.81 | $2.76 - $2.89 | +3.56% | Beat | -13.6% | 16 | 1 up, 3 down | Jul 27, 2023 | $13.87B |
| Mar 31, 2023 | $2.46 | $2.49 | $2.36 - $2.64 | -1.20% | Miss | -22.2% | 14 | 4 up, 2 down | Apr 27, 2023 | $12.22B |
| Dec 31, 2022 | $3.60 | $3.58 | $3.51 - $3.66 | +0.56% | Beat | +8.8% | 17 | 2 up, 1 down | Feb 9, 2023 | $15.12B |
| Sep 30, 2022 | $3.66 | $3.57 | $3.51 - $3.70 | +2.52% | Beat | +9.9% | 15 | 2 up, 1 down | Oct 28, 2022 | $14.81B |
| Jun 30, 2022 | $3.37 | $3.31 | $3.21 - $3.49 | +1.81% | Beat | +8.4% | 15 | 1 up, 3 down | Jul 29, 2022 | $14.58B |
| Mar 31, 2022 | $3.16 | $3.14 | $3.10 - $3.20 | +0.64% | Beat | +7.1% | 16 | 5 up, 1 down | Apr 29, 2022 | $13.54B |
| Dec 31, 2021 | $3.31 | $3.28 | $3.21 - $3.39 | +0.91% | Beat | +13.4% | 16 | 6 up, 2 down | Feb 2, 2022 | $14.89B |
| Sep 30, 2021 | $3.33 | $3.22 | $3.13 - $3.27 | +3.42% | Beat | +17.7% | 13 | N/A | Oct 29, 2021 | $14.34B |
| Jun 30, 2021 | $3.11 | $3.03 | N/A | +2.64% | Beat | +32.9% | 16 | N/A | Jul 30, 2021 | $13.96B |
| Mar 31, 2021 | $2.95 | $2.83 | $2.76 - $3.02 | +4.24% | Beat | +21.9% | 16 | N/A | Apr 30, 2021 | $13.01B |
| Dec 31, 2020 | $2.92 | $2.85 | $2.74 - $2.90 | +2.46% | Beat | +32.1% | 18 | N/A | Feb 3, 2021 | $13.86B |
| Sep 30, 2020 | $2.83 | $2.77 | $2.70 - $2.88 | +2.17% | Beat | +21.5% | 15 | N/A | Oct 30, 2020 | $12.90B |
| Jun 30, 2020 | $2.34 | $2.20 | $1.86 - $2.49 | +6.36% | Beat | +3.5% | 11 | N/A | Jul 31, 2020 | $10.43B |
| Mar 31, 2020 | $2.42 | $2.25 | $2.01 - $2.31 | +7.56% | Beat | +13.1% | 11 | N/A | May 1, 2020 | $8.62B |
| Dec 31, 2019 | $2.21 | $2.19 | $2.17 - $2.22 | +0.91% | Beat | +16.3% | 10 | N/A | Feb 7, 2020 | $8.70B |
| Sep 30, 2019 | $2.33 | $2.30 | $2.23 - $2.36 | +1.30% | Beat | +8.9% | 8 | N/A | Nov 1, 2019 | $8.48B |
| Jun 30, 2019 | $2.26 | $2.21 | $2.19 - $2.23 | +2.26% | Beat | +13.0% | 9 | N/A | Jul 26, 2019 | $8.26B |
| Mar 31, 2019 | $2.14 | $2.07 | $2.01 - $2.10 | +3.38% | Beat | +14.4% | 15 | N/A | Apr 25, 2019 | $7.83B |
| Dec 31, 2018 | $1.90 | $1.93 | $1.86 - $2.03 | -1.55% | Miss | +28.4% | 13 | N/A | Jan 25, 2019 | $8.30B |
| Sep 30, 2018 | $2.14 | $2.00 | $1.93 - $2.06 | +7.00% | Beat | +51.8% | 17 | N/A | Nov 2, 2018 | $8.24B |
| Jun 30, 2018 | $2.00 | $1.97 | $1.91 - $2.05 | +1.52% | Beat | +40.8% | 17 | N/A | Jul 27, 2018 | $8.28B |
| Mar 31, 2018 | $1.87 | $1.79 | $1.75 - $1.85 | +4.47% | Beat | +46.1% | 19 | N/A | Apr 26, 2018 | $7.93B |
| Dec 31, 2017 | $1.48 | $1.43 | $1.42 - $1.51 | +3.50% | Beat | +23.3% | 16 | N/A | Jan 26, 2018 | $7.74B |
| Sep 30, 2017 | $1.41 | $1.39 | $1.36 - $1.42 | +1.44% | Beat | +16.5% | 17 | N/A | Oct 27, 2017 | $7.00B |
| Jun 30, 2017 | $1.42 | $1.40 | $1.35 - $1.42 | +1.43% | Beat | +12.7% | 18 | N/A | Jul 28, 2017 | $6.94B |
| Mar 31, 2017 | $1.28 | $1.26 | N/A | +1.59% | Beat | +11.3% | N/A | N/A | Apr 27, 2017 | $6.54B |
| Dec 31, 2016 | $1.20 | $1.20 | N/A | 0.00% | In line | +6.2% | N/A | N/A | Jan 27, 2017 | $6.80B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $10.00, down 1.2% from the year before. It was $4.82 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $10.00 | -1.2% |
| Dec 31, 2024 | $10.12 | -8.9% |
| Dec 31, 2023 | $11.11 | -19.4% |
| Dec 31, 2022 | $13.79 | +8.6% |
| Dec 31, 2021 | $12.70 | +20.8% |
| Dec 31, 2020 | $10.51 | +17.6% |
| Dec 31, 2019 | $8.94 | +13.0% |
| Dec 31, 2018 | $7.91 | +41.5% |
| Dec 31, 2017 | $5.59 | +16.0% |
| Dec 31, 2016 | $4.82 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,800 words across 17 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,819 | 17 | |
| 2026Q2 | Jun 30, 2026 | 7,245 | 17 | |
| 2026Q1 | Mar 31, 2026 | 10,404 | 16 | |
| 2025Q4 | Dec 31, 2025 | 9,846 | 17 | |
| 2025Q3 | Sep 30, 2025 | 10,376 | 18 | |
| 2025Q2 | Jun 30, 2025 | 7,051 | 17 | |
| 2025Q1 | Mar 31, 2025 | 11,388 | 20 | |
| 2024Q4 | Dec 31, 2024 | 9,170 | 16 |
2026Q3 Earnings Call
Opening remarks
Elizabeth Shea Senior Vice President, Investor Relations Good morning, and thanks for joining us. Also on the call with me today are Rob Michael, Chairman and Chief Executive Officer; Jeff Stewart, Executive Vice President, Chief Commercial Officer; Roopal Thakkar, Executive Vice President, Research and Development, Chief Scientific Officer; and Scott Reents, Executive Vice President, Chief Financial Officer. Before we get started, I'll note that some statements we make today may be considered forward-looking statements based on our current expectations. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements. Additional information about these risks and uncertainties is included in our SEC filings. AbbVie undertakes no obligation to update these forward-looking statements, except as required by law. On today's conference call, non-GAAP financial measures will be used to help investors understand AbbVie's business performance. These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. Following our prepared remarks, we'll take your questions. So with that, I'll turn the call over to Rob.
Robert Michael Chairman and Chief Executive Officer Thank you, Liz. Good morning, everyone, and thank you for joining us. AbbVie continues to perform above our expectations, with another quarter of outstanding results. We are delivering top-tier sales and earnings growth and making significant progress advancing our pipeline. Given the strength of our business and our promising outlook, we are once again raising our full-year guidance and increasing our quarterly dividend. Turning to our third-quarter performance, we achieved adjusted earnings per share of $3.82, which is $0.07 above our guidance midpoint. Total net revenues were $17.4 billion, beating our expectations by $200 million and reflecting robust sales growth of more than 10%. This includes 9 key products that delivered double-digit growth. Based on the strong performance across our business, including Skyrizi, Rinvoq, Vraylar, Ubrelvy, Qulipta and Venclexta, we are raising our full-year revenue guidance by $200 million and have now raised total revenue by $800 million since the start of the year. Further underscoring our confidence in our long-term outlook, today, we announced a 5.2% increase in our quarterly cash dividend, beginning with the dividend payable in February 2027. Since inception, we have grown our quarterly dividend by more than 350%. Turning now to R&D. We are making excellent progress advancing our pipeline to help drive growth in the 2030s and beyond. In immunology, we completed the acquisition of Apogee Therapeutics, adding multiple differentiated assets in dermatology, respiratory and other related inflammatory diseases with significant sales potential. The lead asset, zumilokibart, will be starting Phase III development in atopic dermatitis later this year. Also in immunology, we received U.S.
Frequently Asked Questions About ABBV
When is AbbVie's next earnings date?
AbbVie's next earnings report is expected for Feb 2, 2027.
Did ABBV beat earnings estimates last quarter?
Yes. AbbVie reported EPS of $3.82 for the quarter ended Sep 30, 2026, above the $3.74 estimate, a 2.14% surprise.
What EPS do analysts expect from ABBV next quarter?
The consensus EPS estimate for AbbVie for the quarter ending Dec 31, 2026 is $3.95 from 26 analysts, with estimates from $3.73 to $4.21.
How often does ABBV beat earnings estimates?
AbbVie beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +1.86%.
ABBV pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts